Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CHRM1CHRM2CHRM3CHRM4ESR1ESR2GABRA1GABRB1GABRG2GBA1HRH1HTR1DHTR2AOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Oxedrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 6/20 | 0.70 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.70 |
| ▸ | ADRA2A known ✓ | P08913 | 4/20 | 0.51 |
| ▸ | ADRA2B known ✓ | P18089 | 4/20 | 0.51 |
| ▸ | ADRA2C known ✓ | P18825 | 4/20 | 0.51 |
| ▸ | ADRB1 known ✓ | P08588 | 3/20 | 0.51 |
| ▸ | ADRB3 known ✓ | P13945 | 3/20 | 0.51 |
| ▸ | ADRA1A known ✓ | P35348 | 2/20 | 0.51 |
| ▸ | ADRA1B known ✓ | P35368 | 2/20 | 0.51 |
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.51 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.77 |
| ▸ | TDP1 | Q9NUW8 | 7/20 | 0.77 |
| ▸ | HIF1A | Q16665 | 7/20 | 0.77 |
| ▸ | BLM | P54132 | 6/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.77 |
| ▸ | THPO | P40225 | 2/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.77 |
| ▸ | HTR1A | P08908 | 2/20 | 0.77 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxedrine SCHEMBL30559825 | 1.00 | KDM4E (0.77) | KDM4ETDP1HIF1ABLMALDH1A1 | |
| Oxedrine SCHEMBL28002395 | 0.90 | HIF1A (0.82) | KDM4ETDP1HIF1ABLMALDH1A1 | |
| Oxedrine SCHEMBL17726874 | 0.88 | KDM4E (1.00) | KDM4ETDP1HIF1ABLMALDH1A1 | |
| Oxedrine SCHEMBL146500 | 0.88 | KDM4E (1.00) | KDM4ETDP1HIF1ABLMALDH1A1 | |
| Oxedrine SCHEMBL2283013 | 0.88 | KDM4E (1.00) | KDM4ETDP1HIF1ABLMALDH1A1 | |
| Oxedrine SCHEMBL28287981 | 0.88 | KDM4E (1.00) | KDM4ETDP1HIF1ABLMALDH1A1 | |
| Oxedrine SCHEMBL1487703 | 0.86 | KDM4E (0.96) | KDM4ETDP1HIF1ABLMALDH1A1 | |
| Racepinephrine SCHEMBL4406973 | 0.83 | KDM4E (1.00) | KDM4ETDP1HIF1ABLMALDH1A1 | |
| L-Adrenaline SCHEMBL20608410 | 0.83 | KDM4E (1.00) | KDM4ETDP1HIF1ABLMALDH1A1 | |
| Epinephrine SCHEMBL40741 | 0.83 | KDM4E (1.00) | KDM4ETDP1HIF1ABLMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104876828-A | Method for synthesizing synephrine, its hydrochloride and tartrate | LI YUSHAN | 2015-09-02 | — | — | CN | claimed |
| US-10675278-B2 | Crush resistant delayed-release dosage forms | Grünenthal GmbH (DE) | 2020-06-09 | — | — | US | disclosed |
| US-20180369235-A1 | CRUSH RESISTANT DELAYED-RELEASE DOSAGE FORMS | Grünenthal GmbH (DE) | 2018-12-27 | — | — | US | disclosed |
| US-10160719-B2 | Pharmaceutical salts | GRUNENTHAL GMBH (DE) | 2018-12-25 | — | — | US | disclosed |
| US-20170312271-A1 | CRUSH RESISTANT DELAYED-RELEASE DOSAGE FORMS | Grünenthal GmbH (DE) | 2017-11-02 | — | — | US | disclosed |
| US-9750701-B2 | Pharmaceutical dosage form | Grünenthal GmbH (DE) | 2017-09-05 | — | — | US | disclosed |
| CN-102014877-B | Pharmaceutical dosage form | 格吕伦塔尔有限公司 | 2017-06-06 | — | — | CN | disclosed |
| US-20170137370-A1 | PHARMACEUTICAL SALTS | Grünenthal GmbH (DE) | 2017-05-18 | — | — | US | disclosed |
| US-20160369237-A1 | METHODS TO ACCELERATE THE ISOLATION OF NOVEL CELL STRAINS FROM PLURIPOTENT STEM CELLS AND CELLS OBTAINED THEREBY | ADVANCED CELL TECH INC (US) | 2016-12-22 | — | — | US | disclosed |
| US-20160199305-A1 | PHARMACEUTICAL DOSAGE FORM | Grünenthal GmbH (DE) | 2016-07-14 | — | — | US | disclosed |
| US-7294345-B2 | Otorhinological delivery device | SCHERING OY (FI) | 2007-11-13 | — | — | US | disclosed |
| WO-2007062198-A1 | METHODS TO ACCELERATE THE ISOLATION OF NOVEL CELL STRAINS FROM PLURIPOTENT STEM CELLS AND CELLS OBTAINED THEREBY | ADVANCED CELL TECHNOLOGY, INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2006135602-A2 | HERPES VIRUS-BASED COMPOSITIONS AND METHODS OF USE IN THE PRENATAL AND PERINATAL PERIODS | UNIVERSITY OF ROCHESTER (US) | 2006-12-21 | — | — | WO | disclosed |
| CN-1870990-A | Fused phenylalanine derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes | MERCK & CO INC (US) | 2006-11-29 | — | — | CN | disclosed |
| US-20060193914-A1 | Crush resistant delayed-release dosage forms | ENDO PHARMACEUTICALS, INC. | 2006-08-31 | — | — | US | disclosed |
| US-20060067982-A1 | Otorhinological delivery device | TIMO HAAPAKUMPU HARRI JUKARA JUHA ALA -SORVARI HEN (FI) | 2006-03-30 | — | — | US | disclosed |
| US-20050176790-A1 | Pharmaceutical salts | GRUNENTHAL GMBH (DE) | 2005-08-11 | — | — | US | disclosed |
| CN-1561203-A | Pharmaceutically acceptable salts | GRUENENTHAL GMBH (DE) | 2005-01-05 | — | — | CN | disclosed |
| WO-2004064912-A1 | AN OTORHINOLOGICAL DELIVERY DEVICE | SCHERING OY (FI) | 2004-08-05 | — | — | WO | disclosed |
| EP-1438942-A1 | An otorhinological drug delivery device | Schering Oy (FI) | 2004-07-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176790-A1 | Pharmaceutical salts | SLC5A1, SLC5A2, SLC35A1 | ADRB2 1293/4885SLC6A2 217/4885ADRA2A 1469/4885 |
| US-10160719-B2 | Pharmaceutical salts | SLC5A1, SLC5A2, SLC35A1 | ADRB2 1346/4885SLC6A2 164/4885ADRA2A 1563/4885 |
| US-20170137370-A1 | PHARMACEUTICAL SALTS | SLC5A1, SLC5A2, SLC35A1 | ADRB2 1346/4885SLC6A2 164/4885ADRA2A 1563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.